SCHOTT to Triple Vial Production Capacity in the US
SCHOTT is planning to triple its ready-to-use vial production capacity in the United States to meet increasing demand for storing injectable drugs.
SCHOTT has announced plans to triple its ready-to-use vial production capacity at its site in Lebanon, PA, to meet increasing demand for storing injectable drugs. The company currently provides a comprehensive product portfolio for ready-to-use vials with more than 750 product combinations.
Ready-to-use vials are particularly suitable for drugs, such as biologics and vaccines. The vials are pre-washed and sterilized and packaged in a standardized tub to simplify the filling process for pharmaceutical companies. The solution enables pharma companies to efficiently perform pre-clinical and clinical trials as well as commercial filling.
“With our investment, we are underlining our commitment to the global pharma industry and particularly the U.S. market. Additionally, we are enhancing our regional manufacturing footprint in Lebanon, Pennsylvania, where we are proudly celebrating our site’s 30th anniversary,” said Andreas Reisse, executive vice president of SCHOTT Pharma, in a press release.
“We are increasing our production capacity intending to meet the growing need for this product category and contribute to bringing the latest life-saving treatments to patients faster,” said Hakan Gerdan, who was appointed as SCHOTT’s new Plant Manager in Lebanon, PA at the start of 2022, in the release.
Source: SCHOTT
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
